Flupirtine-d4 (hydrochloride) (Synonyms: D 9998-d4 hydrochloride) |
رقم الكتالوجGC45761
One-Click Copy Product Info
|
Flupirtine-d4 (D 9998-d4) هيدروكلوريد هو الديوتيريوم المسمى Flupirtine.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1324717-75-0
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Flupirtine-d4 is intended for use as an internal standard for the quantification of flupirtine by GC- or LC-MS. Flupirtine is an activator of voltage-gated potassium channel 7 (Kv7/KCNQ).1,2,3 It induces relaxation of preconstricted pulmonary arteries isolated from wild-type and serotonin transporter-overexpressing (SERT+) mice.2 Flupirtine (30 mg/kg per day) decreases mean right ventricular pressure and right ventricular hypertrophy in hypoxia-induced and SERT+ mouse models of pulmonary arterial hypertension. It increases the paw withdrawal threshold in a rat model of streptozotocin-induced diabetic neuropathy when administered at a dose of 10 mg/kg and increases paw withdrawal latency in a rat model of carrageenan-induced paw inflammation when used in combination with morphine.3 Flupirtine also indirectly antagonizes NMDA receptors via its effects on potassium channels.1,4
|1. Devulder, J. Flupirtine in pain management: Pharmacological properties and clinical use. CNS Drugs 25(10), 867-881 (2010).|2. Morecroft, I., Murray, A., Nilsen, M., et al. Treatment with the Kv7 potassium channel activator flupirtine is beneficial in two independent mouse models of pulmonary hypertension. Br. J. Pharmacol. 157(7), 1241-1249 (2009).|3. Goodchild, C.S., Kolosov, A., Tucker, A.P., et al. Combination therapy with flupirtine and opioid: Studies in rat pain models. Pain Med. 9(7), 928-938 (2008).|4. Kornhuber, J., Bleich, S., Wiltfang, J., et al. Flupirtine shows functional NMDA receptor antagonism by enhancing Mg2+ block via activation of voltage independent potassium channels. J. Neural Transm. (Vienna) 106(9-10), 857-867 (1999).
| Cas No. | 1324717-75-0 | SDF | |
| المرادفات | D 9998-d4 hydrochloride | ||
| Canonical SMILES | FC(C([2H])=C1[2H])=C([2H])C([2H])=C1CNC2=CC=C(NC(OCC)=O)C(N)=N2.Cl | ||
| Formula | C15H13D4FN4O2.HCl | M.Wt | 344.8 |
| الذوبان | Acetone: slightly soluble,Methanol: slightly soluble,Water: slightly soluble | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.9002 mL | 14.5012 mL | 29.0023 mL |
| 5 mM | 580 μL | 2.9002 mL | 5.8005 mL |
| 10 mM | 290 μL | 1.4501 mL | 2.9002 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 25 reference(s) in Google Scholar.)